PPARGC1A and melanoma: Chronic PLX4032 treated G361 and SKMEL5, however, yielded resistant cells with elevated PPARGC1A expression (Supplementary Fig. 1c), which parallels the other end of the change-in-expression continuum seen across melanoma biopsies pre-/post-BRAF inhibitor treatment (Fig. 1a).